Imeglyn 1000 Tablet SR contains Imeglimin 1000 mg as its active ingredient, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts by targeting mitochondrial bioenergetics, improving insulin sensitivity, enhancing glucose-stimulated insulin secretion, and reducing hepatic glucose production. This multifaceted mechanism helps achieve better glycemic control in patients with inadequate response to diet and exercise alone. The sustained-release formulation ensures a gradual release of the active compound, providing stable plasma concentrations and improving patient compliance through once or twice-daily dosing. Imeglyn 1000 Tablet SR is typically prescribed as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin, under medical supervision. Clinical trials have demonstrated its efficacy in lowering HbA1c levels with a favorable safety profile, exhibiting minimal risk of hypoglycemia and weight neutrality. Common adverse effects may include mild gastrointestinal disturbances such as nausea or diarrhea, which are generally transient. Imeglyn should be used cautiously in patients with renal or hepatic impairment, and dose adjustments may be necessary. Regular monitoring of blood glucose and renal function is recommended during therapy to optimize treatment outcomes and ensure patient safety.